Cardiovascular Clinical Trials Market

Cardiovascular Clinical Trials Market Size Survey Report – In a Glance

As per the survey report on global Cardiovascular clinical trials market, the market is projected to foresee a CAGR of 6.2% between 2024-2033, and further generate a market size of USD 10.1 billion revenue by the end of 2033. In the year 2024, the market size was valued at USD 5.9 billion revenue.

• The global Cardiovascular clinical trials market is projected to grow on account of the rising prevalence of cardiovascular diseases.
• In Japan, the Cardiovascular clinical trials market growth can be attributed to the rising geriatric population.
• KDMI analyst’s growth analysis foresees challenges in patient recruitment and retention to challenge the market growth.
• North America, having the highest market share in the Cardiovascular clinical trials market, is projected to dominate the global market.

Cardiovascular Clinical Trials Market Analysis

Cardiovascular clinical trials are scientific studies that analyze to prevent, treat, detect, or manage cardiovascular diseases and whose trial involves assessing new drugs, procedures, tools, and behavioral assistance. The rising prevalence of cardiovascular diseases is the leading factor that ensures the continued growth of the cardiovascular clinical trials market across the globe. As mentioned in reports, each year nearly 17.9 million people succumb to death, making cardiovascular diseases (CVDs) the key cause of death worldwide. It has also been reported that more than 0.5 billion people on a global scale continue to be affected by cardiovascular diseases, which are responsible for 20.5 million deaths in 20211 that is close to a third of all deaths across the world and a net increase on the roughly calculated 121 million CVD deaths. IQVIA Inc, ICON plc, Eli Lilly and Company, are some of the significant parties in the global market for Cardiovascular clinical trials.

Analyst’s Observation on Japan Cardiovascular clinical trials Market Survey

In Japan, the market growth for Cardiovascular clinical trials can be attributed to the rising geriatric population as the demand for cardiovascular drugs to handle and treat age-associated heart diseases is surging as the population becomes older. In the view of the National Cerebral and Cardiovascular Center, Japan, the total count of heart failure patients in Japan was estimated to be close to 1.2 million in December 2021. Furthermore, as reported by the same source, the occurrence rate of cardiovascular diseases elevates with age, and the number of heart failure patients is predicted to advance more in Japan, where people achieve 100 years of age. Additionally, Japan has the world's fastest-aging population, and near about 29% of Japan's population was 65 and above in 2021, as per the World Data 2022 records. Pfizer Inc., Bayer AG, Takeda Pharmaceutical Co Ltd., are some of the significant parties in the market for Cardiovascular clinical trials in Japan.

Cardiovascular Clinical Trials Market Growth Driver and Challenges

Growth Driver

Rise in contract research organization (CRO):

The pharmaceutical industries illuminated progressive and potential-filled pipelines with an extraordinary number of developing cardiovascular drugs covering a variety of experimental drugs from preclinical, early, mid, and late phases, to post-commercialization tracking. The climbing number indicates the necessity for ongoing clinical trials to assess drug safety and effectiveness. Several data by the Congressional Budget Office reveal that the average R&D cost varies from USD 1 billion to more than USD 2 billion and the demand for cardiac and clinical additional trials continued to grow the costs associated with research and development in cardiovascular testing. It has been found that 4,232 Contract Research Organizations businesses exist in the US as of 2023, which expanded by 3.6% from 2022 and the total business counts in the Contract Research Organizations industry in the US has escalated by 3.6% per year on average over the five years between 2018 - 2023. Furthermore, as a whole in America, 4,200 Contract Research Organizations businesses are available currently as of 2023 that were 4% less in 2022.

Restraint

Challenges in patient recruitment and retention:

Several obstacles and challenges encompass the patient’s denial to travel a long distance to take part in clinical trials since it is a cumbersome procedure, yielding low recruitment and high drop-out rates. Distributed clinical trials provide flexibility in the process and are more convenient promising better retention. Various barriers include a lack of proper knowledge about the healthcare system, limited availability of healthcare, and illiteracy, which can be improved by technological developments and well-established health organizations. The report states that 55% of clinical trials are halted due to low recruitment, with an average enrollment success rate of 40% for Phase III and IV trials worldwide. More than 80% of clinical trial attempts are unable to register, prolonging the research and adding new study sites. More than 80% of clinical trials are unable to accomplish targeted patient enrollment, and 30% of study participants discontinue participation, in the United States.

Cardiovascular Clinical Trials Market Segmentation

Our experts at KD Market Insights have segmented the global Cardiovascular clinical trials market research report as:

Cardiovascular Clinical Trials Market Regional Synopsis

The North America Cardiovascular clinical trials market is majorly driven by the ground-breaking innovative medical technologies, presence of high-tech infrastructure, and conduction of several clinical trials for heart diseases. U.S. and Canada lead the cardiovascular clinical trials market in the region due to the existence of highly skilled healthcare professionals, cutting-edge medical technologies, and developed research centers. It was found that about 5,068 cardiovascular clinical studies are registered in the United States as of September 2023.  Also, cardiovascular disease (CVD) was the major cause of mortality in the United States with approximately 928,741 deaths in the year 2020 where coronary heart disease (CHD) was the key cause (41.2%) of deaths resulting from CVD in the United States, followed by stroke (17.3%), other CVD (16.8%), high blood pressure (12.9%), heart failure (9.2%), diseases of the arteries (2.6%).

Asia-Pacific is foreseen to grow at the fastest CAGR of 6.9% during the forecast period due to their facilitative policy reforms and financially viable options for clinical research and development, especially in China and India. As an example, in 2022, in accordance with the National Center for Biotechnology Information, India has become a favored country for international pharmaceutical companies to conduct clinical trials, as India has an enhanced patient recruitment capability and swiftly diminishing clinical trial costs. Furthermore, the total death count of CVD-related patients in Asia escalated from 5.6 million to 1.08 million, over the last 20 years close to 39% of CVD deaths occurred in individuals below 70 years of age, which was considerably higher than premature CVD deaths in the United States that were about 23%.

As per our analysts at KD Market Insights, the following five players lead the North America Cardiovascular clinical trials market growth:

• Caidya
• Vial
• Medpace, Inc.
• Thermo Fisher Scientific
• Merck & Co

Cardiovascular clinical trials Market Competitive Landscape

Some of the key players who top the global Cardiovascular clinical trials market share:

• ICON plc
• Eli Lilly and Company
• Syneos Health
• Worldwide Clinical Trials
• Veeda Clinical Research
• IQVIA Inc
• SGS SA
• PPD Inc
• Caidya
• Vial
• Medpace, Inc.
• Thermo Fisher Scientific
• Merck & Co
• Pfizer

1. Executive Summary
   1. Market Overview
   2. Key Findings
   3. Market Trends
   4. Market Outlook
2. Introduction
   1. Scope of the Report
   2. Research Methodology
   3. Definitions and Assumptions
   4. Acronyms and Abbreviations
3. Market Dynamics
   1. Drivers
   2. Restraints
   3. Opportunities
   4. Challenges
4. Global Cardiovascular Clinical Trials Market
   1. Market Overview
   2. Market Size and Forecast
   3. Market Segmentation
      1. By Phase
      2. By Study design
      3. By Indication
      4. By Region
5. Market Segmentation by Phase
   1. 1. Phase I
      2. Phase II
      3. Phase III
      4. Phase IV
6. Market Segmentation by Study design
   1. 1. Interventional
      2. Observational
      3. Expanded access
7. Market Segmentation by Indication
   1. 1. Acute Coronary Syndrome
      2. Coronary Artery Disease
      3. Ischemic Heart Disease
      4. Pulmonary Arterial Hypertension
      5. Stroke
      6. Cardiac Arrhythmias
      7. Heart Failure
      8. Others
8. Regional Analysis
   1. North America
      1. United States
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Phase, Study design, and Indication
      2. Canada
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Phase, Study design, and Indication
      3. Mexico
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Phase, Study design, and Indication
   2. Europe
      1. United Kingdom
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Phase, Study design, and Indication
      2. Germany
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Phase, Study design, and Indication
      3. France
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Phase, Study design, and Indication
      4. Italy
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Phase, Study design, and Indication
      5. Spain
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Phase, Study design, and Indication
      6. Rest of Europe
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Phase, Study design, and Indication
   3. Asia Pacific
      1. China
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Phase, Study design, and Indication
      2. Japan
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Phase, Study design, and Indication
      3. India
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Phase, Study design, and Indication
      4. Australia
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Phase, Study design, and Indication
         4. South Korea
         5. Market Size and Forecast
         6. Key Trends and Developments
         7. Market Analysis by Phase, Study design, and Indication
      5. Rest of Asia Pacific
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Phase, Study design, and Indication
   4. Latin America
      1. Brazil
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Phase, Study design, and Indication
      2. Argentina
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Phase, Study design, and Indication
      3. Colombia
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Phase, Study design, and Indication
      4. Rest of Latin America
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Phase, Study design, and Indication
   5. Middle East & Africa
      1. South Africa
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Phase, Study design, and Indication
      2. Saudi Arabia
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Phase, Study design, and Indication
      3. UAE
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Phase, Study design, and Indication
      4. Rest of Middle East & Africa
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Phase, Study design, and Indication
9. Competitive Landscape
   1. Market Share Analysis
   2. Company Profiles
   3. Medtronic (Ireland)
   4. IBM
   5. Apple Inc.
   6. Siemens Medical Solutions
   7. Pepperl+Fuchs
   8. Cisco
   9. GE Healthcare
10. Strategic Recommendations
11. Appendix
    1. List of Tables
    2. List of Figures
12. References